ID

6181

Descripción

ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588

Link

http://clinicaltrials.gov/ct2/show/record/NCT00952588

Palabras clave

Versiones (4)
  1. 14/11/11 14/11/11 -
  2. 6/12/13 6/12/13 - Martin Dugas
  3. 11/4/14 11/4/14 - Julian Varghese
  4. 16/12/14 16/12/14 - Martin Dugas
Subido en

16 de diciembre de 2014

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility AZD1152 and LDAC in AML

Inglés

Eligibility AZD1152 and LDAC in AML

1 formularios  
Inclusion criteria
Descripción

Inclusion criteria

Alias
UMLS CUI-1
C1512693
Provision of written informed consent
Descripción

consent

Tipo de datos

boolean

Alias
UMLS CUI-1
C0021430
Newly diagnosed male or female patients aged 60 and over
Descripción

Newly diagnosed patients aged 60 and over

Tipo de datos

boolean

Alias
UMLS CUI-1
C0001779
De Novo or Secondary AML
Descripción

De Novo or Secondary AML

Tipo de datos

boolean

Alias
UMLS CUI-1
C0023467
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
Descripción

Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia

Tipo de datos

boolean

Alias
UMLS CUI-1
C3242266
UMLS CUI-2
C0600558
Exclusion criteria
Descripción

Exclusion criteria

Alias
UMLS CUI-1
C0680251
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
Descripción

Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product

Tipo de datos

boolean

Alias
UMLS CUI-1
C2348568
Administration of LDAC is clinically contraindicated
Descripción

Administration of LDAC is clinically contraindicated

Tipo de datos

boolean

Alias
UMLS CUI-1
C1301624
UMLS CUI-2
C0010711
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
Descripción

Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)

Tipo de datos

boolean

Alias
UMLS CUI-1
C0023487
Patients with blast crisis of chronic myeloid leukaemia
Descripción

Patients with blast crisis of chronic myeloid leukaemia

Tipo de datos

boolean

Alias
UMLS CUI-1
C0023473
UMLS CUI-2
C0005699
Volver a la parte superior de la página

Similar models

Eligibility AZD1152 and LDAC in AML

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI-1)
consent
Item
Provision of written informed consent
boolean
C0021430 (UMLS CUI-1)
Age
Item
Newly diagnosed male or female patients aged 60 and over
boolean
C0001779 (UMLS CUI-1)
AML
Item
De Novo or Secondary AML
boolean
C0023467 (UMLS CUI-1)
Patient not eligible for Induction therapy
Item
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
boolean
C3242266 (UMLS CUI-1)
C0600558 (UMLS CUI-2)
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
other trial
Item
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
boolean
C2348568 (UMLS CUI-1)
Contraindication LDAC
Item
Administration of LDAC is clinically contraindicated
boolean
C1301624 (UMLS CUI-1)
C0010711 (UMLS CUI-2)
AML M3 APL
Item
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
boolean
C0023487 (UMLS CUI-1)
CML blast crisis
Item
Patients with blast crisis of chronic myeloid leukaemia
boolean
C0023473 (UMLS CUI-1)
C0005699 (UMLS CUI-2)
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial